Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.

Toxicity testing has been ineffective in the prediction of drug candidates that will be associated with a relatively high incidence of idiosyncratic drug reactions (IDRs). Circumstantial evidence suggests the involvement of reactive metabolites in the aetiology of these reactions and this has prompted several companies to screen drug candidates for the formation of such compounds. Most drugs form at least one reactive metabolite. To develop efficient prediction methods, a better understanding of the basic mechanisms involved is essential. This review highlights the current mechanistic hypotheses of IDRs and discusses future directions in the development of better predictive tests.

[1]  J. Uetrecht,et al.  N-OXIDATION OF DRUGS ASSOCIATED WITH IDIOSYNCRATIC DRUG REACTIONS , 2002, Drug metabolism reviews.

[2]  M Pirmohamed,et al.  Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. , 1998, Chemical research in toxicology.

[3]  L. Benet,et al.  Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. , 2002, Chemical research in toxicology.

[4]  B. Sachs,et al.  Allergic and autoimmune reactions to xenobiotics: how do they arise? , 1998, Immunology today.

[5]  A. Scheen.  Hepatotoxicity with Thiazolidinediones , 2001, Drug safety.

[6]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[7]  M. Abu-Asab,et al.  Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. , 2003, Chemical research in toxicology.

[8]  P. Woster,et al.  A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. , 2000, The Journal of investigative dermatology.

[9]  C. Janeway,et al.  Innate immune recognition and control of adaptive immune responses. , 1998, Seminars in immunology.

[10]  W. Pichler.  Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept , 2002, Current opinion in allergy and clinical immunology.

[11]  M. Pirmohamed,et al.  Immunological Principles of Adverse Drug Reactions , 2000, Drug safety.

[12]  D. Solomon,et al.  Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. , 1979, JAMA.

[13]  J. Messenheimer,et al.  Safety Review of Adult Clinical Trial Experience with Lamotrigine , 1998, Drug safety.

[14]  J. Uetrecht,et al.  Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. , 1999, The Journal of pharmacology and experimental therapeutics.

[15]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[16]  T. Baillie,et al.  Mass spectrometry in the analysis of glutathione conjugates. , 1993, Biological mass spectrometry.

[17]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[18]  U. Boelsterli.  Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. , 2002, Current drug metabolism.

[19]  H. Satoh,et al.  The immunologic and metabolic basis of drug hypersensitivities. , 1988, Annual review of pharmacology and toxicology.

[20]  J. Uetrecht,et al.  Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. , 1994, The Journal of pharmacology and experimental therapeutics.

[21]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[22]  T. Baillie.  Chemically Reactive Metabolites in Drug Discovery and Development , 2003 .

[23]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[24]  Martyn T. Smith,et al.  Mechanisms of troglitazone hepatotoxicity. , 2003, Chemical research in toxicology.

[25]  J. Uetrecht,et al.  New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. , 1999, Chemical research in toxicology.

[26]  T. Baillie,et al.  Drug metabolites in safety testing. , 2002, Toxicology and applied pharmacology.

[27]  T. Monks,et al.  The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. , 2002, Current drug metabolism.

[28]  C. D. Thompson,et al.  Mechanisms of idiosyncratic drug reactions: the case of felbamate. , 2002, Chemico-biological interactions.

[29]  J. Uetrecht,et al.  Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. , 2002, Current drug metabolism.

[30]  M. Pirmohamed,et al.  The danger hypothesis--potential role in idiosyncratic drug reactions. , 2002, Toxicology.